株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Anavex Life Sciences Corp.の製品パイプライン分析

Anavex Life Sciences Corp. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 240907
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
Anavex Life Sciences Corp.の製品パイプライン分析 Anavex Life Sciences Corp. - Product Pipeline Review - 2015
出版日: 2015年02月28日 ページ情報: 英文 39 Pages
概要

当レポートでは、Anavex Life Sciences Corp.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Anavex Life Sciences Corp.の基本情報

Anavex Life Sciences Corp.の概要

  • 主要情報
  • 企業情報

Anavex Life Sciences Corp.:R&Dの概要

  • 主な治療範囲

Anavex Life Sciences Corp.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Anavex Life Sciences Corp.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Anavex Life Sciences Corp.:薬剤プロファイル

  • ANAVEX-2-73
  • AF-710B
  • Anavex Plus
  • ANAVEX-1-41
  • ANAVEX-1005
  • ANAVEX-1007
  • ANAVEX-1066
  • ANAVEX-1079
  • ANAVEX-1519
  • ANAVEX-19-144

Anavex Life Sciences Corp.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Anavex Life Sciences Corp.:最近のパイプライン動向

Anavex Life Sciences Corp.:休止中のプロジェクト

Anavex Life Sciences Corp.:企業発表

Anavex Life Sciences Corp.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06836CDB

Summary

Global Markets Direct's, 'Anavex Life Sciences Corp. - Product Pipeline Review - 2015', provides an overview of the Anavex Life Sciences Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Anavex Life Sciences Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Anavex Life Sciences Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Anavex Life Sciences Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Anavex Life Sciences Corp.'s pipeline products

Reasons to buy

  • Evaluate Anavex Life Sciences Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Anavex Life Sciences Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Anavex Life Sciences Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Anavex Life Sciences Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Anavex Life Sciences Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Anavex Life Sciences Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Anavex Life Sciences Corp. Snapshot
    • Anavex Life Sciences Corp. Overview
    • Key Information
    • Key Facts
  • Anavex Life Sciences Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Anavex Life Sciences Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Anavex Life Sciences Corp. - Pipeline Products Glance
    • Anavex Life Sciences Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Anavex Life Sciences Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Anavex Life Sciences Corp. - Drug Profiles
    • (ANAVEX-273 + donepezil hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-273
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-1037
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-1066
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-1067
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-1079
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-141
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-1519
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANAVEX-371
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anavex Life Sciences Corp. - Pipeline Analysis
    • Anavex Life Sciences Corp. - Pipeline Products by Target
    • Anavex Life Sciences Corp. - Pipeline Products by Route of Administration
    • Anavex Life Sciences Corp. - Pipeline Products by Molecule Type
    • Anavex Life Sciences Corp. - Pipeline Products by Mechanism of Action
  • Anavex Life Sciences Corp. - Recent Pipeline Updates
  • Anavex Life Sciences Corp. - Dormant Projects
  • Anavex Life Sciences Corp. - Company Statement
  • Anavex Life Sciences Corp. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Anavex Life Sciences Corp., Key Information
  • Anavex Life Sciences Corp., Key Facts
  • Anavex Life Sciences Corp. - Pipeline by Indication, 2015
  • Anavex Life Sciences Corp. - Pipeline by Stage of Development, 2015
  • Anavex Life Sciences Corp. - Monotherapy Products in Pipeline, 2015
  • Anavex Life Sciences Corp. - Combination Treatment Modalities in Pipeline, 2015
  • Anavex Life Sciences Corp. - Phase II, 2015
  • Anavex Life Sciences Corp. - Preclinical, 2015
  • Anavex Life Sciences Corp. - Pipeline by Target, 2015
  • Anavex Life Sciences Corp. - Pipeline by Route of Administration, 2015
  • Anavex Life Sciences Corp. - Pipeline by Molecule Type, 2015
  • Anavex Life Sciences Corp. - Pipeline Products by Mechanism of Action, 2015
  • Anavex Life Sciences Corp. - Recent Pipeline Updates, 2015
  • Anavex Life Sciences Corp. - Dormant Developmental Projects,2015

List of Figures

  • Anavex Life Sciences Corp. - Pipeline by Top 10 Indication, 2015
  • Anavex Life Sciences Corp. - Pipeline by Stage of Development, 2015
  • Anavex Life Sciences Corp. - Monotherapy Products in Pipeline, 2015
  • Anavex Life Sciences Corp. - Pipeline by Top 10 Target, 2015
  • Anavex Life Sciences Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Anavex Life Sciences Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Anavex Life Sciences Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top